Breaking News, Collaborations & Alliances

CPDC Enters Clinical Manufacturing Deal with CellBion

CDMO expands into Asia with a development, manufacturing and clinical supply agreement for 177Lu-PSMA (DGUL).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Center for Probe Development and Commercialization (CPDC) has entered a development, manufacturing and supply agreement with CellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. CPDC will develop and manufacture CellBion’s drug product for Phase II clinical supply in South Korea with the goal of expanding into North America. CPDC is a contract development and manufacturing organization (CDMO) for the GMP manufacturing and global distribution of radiotherapeutics. &#82...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters